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Vogt-Koyanagi-Harada (VKH) disease is a systemic autoimmune disorder against melanocytes. Recent studies have
identified multiple genetic factors that might be associated with the pathogenesis of VKH disease. We performed
an electronic database search of PubMed, MEDLINE, and EMBASE, and all relevant papers published up to 13 June
2014 were reviewed. A total of 1,031 publications including articles relevant to the genetics of VKH disease and the
references of these articles were reviewed. The review identified a number of genetic factors which might be
involved in the pathogenesis of VKH disease, some of which may alter the clinical course of VKH disease. Genes
which might be involved in the pathogenesis of VKH disease included genes expressing HLA, complement factor H,
interleukins, cytotoxic T-lymphocyte antigen 4 (CTLA-4), killer cell immunoglobulin-like receptors (KIR), programmed
cell death 1 (PDCD1), protein tyrosine phosphatase non-receptor 22 (PTPN22), osteopontin, tumor necrosis factor
alpha-induced protein 3 (TNFAIP3), macrophage migration inhibitory factor (MIF), and other immune response
genes. Further studies to explore the correlation among different genotypes and phenotypes of VKH disease will be
useful to shed light on the pathogenesis of uveitis in VKH disease and may facilitate the development of new
treatment modalities of uveitis in VKH disease.
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Introduction
Vogt-Koyanagi-Harada (VKH) disease is a systemic auto-
immune disorder against melanocytes and affects the eyes,
skin, ears, and meninges [1-4]. VKH disease usually occurs
more frequently in females with a female-to-male ratio of
approximately 2:1 and is one of the top three leading
causes of uveitis in China [4-6]. It is characterized by bilat-
eral granulomatous uveitis and can be classified into four
stages: prodromal, uveitic, convalescence, and chronic
recurrent [7]. In the prodromal and uveitic phases, there
are neurological and auditory manifestations, and integu-
mentary findings usually appear in the convalescent and
chronic recurrent phases of the disease [2]. Together with
the absence of past ocular surgery, the ocular, neuro-
logical, auditory, and integumentary findings help to es-
tablish the diagnosis of VKH disease [8]. Treatment for* Correspondence: tyylai@cuhk.edu.hk
Department of Ophthalmology and Visual Sciences, The Chinese University
of Hong Kong, 3/F Hong Kong Eye Hospital, 147K Argyle Street, Kowloon,
Hong Kong
© 2014 Ng et al.; licensee Springer. This is an O
Attribution License (http://creativecommons.or
in any medium, provided the original work is pVKH disease generally involves aggressive systemic cortico-
steroid treatment during the acute stage to reduce the risk
of permanent visual loss [9-12]. Corticosteroid treatment
should be tapered off slowly and maintained for at least
6 months as early withdrawal of oral corticosteroid has
been found to be a significant risk factor for recurrence of
VKH disease and might lead to worse visual outcome [13].
The precise etiology of VKH disease is unclear, and it
has been postulated that pathogenesis involves an auto-
immune process directed against melanocytes triggered by
an infectious agent in genetically susceptible individuals
[1], leading to the loss of melanocytes and subsequent de-
pigmentation [14,15]. The potential role of infection in the
pathogenesis of VKH disease is supported by the presence
of Epstein-Barr virus DNA in vitreous aspiration of a pa-
tient with VKH disease [16], and cross-reactions between
melanocyte peptides and cytomegalovirus envelope glyco-
protein resulting in melanocyte proliferation [17]. How-
ever, a causative association between viral agents and VKH
disease has not yet been established. The autoimmune re-
sponse against melanocytes is complex and involves innate,pen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Ng et al. Journal of Ophthalmic Inflammation and Infection 2014, 4:20 Page 2 of 12
http://www.joii-journal.com/content/4/1/20humoral, and cellular immunity. CD4+ and CD8+ lympho-
cytes, as well as Th17 and regulatory T cells, have all been
implicated in the pathogenesis [18]. High titres of IgG
against KU-MEL-1, an antigen expressed by human mela-
nocytes, have been detected in patients with VKH disease
[19]. Innate immunity may also play an important role in
the pathogenesis of VKH disease as evidenced by the pres-
ence of histiocytic and multinucleated giant cell infiltrates in
enucleated eyes with VKH disease [14]. In combination with
environmental factors, genetic factors are of paramount im-
portance in various immune processes in VKH disease. This
review aims to provide an overview on the role of genetics
in the development of VKH disease and the clinical im-
portance and implications of genetics in VKH disease.
Human leukocyte antigen genes
The major histocompatibility complex (MHC) in human
is known as human leukocyte antigen (HLA). The MHC
region in human is located at 6p21.3 on the short arm of
chromosome 6, containing more than 200 genes and
over 40 of which are HLA genes [20]. The HLA genes
encode a wide variety of antigen-presenting molecules
on cell surface and proteins with immunological func-
tion. The HLA genes involved in immune function are
classified into three classes [20,21]: MHC class I region
contains genes that encode HLA-A, HLA-B, and HLA-C
which form complexes with peptides of antigens and
then export these antigens to the cell surface; MHC class
II region contains genes encoding HLA-DM, HLA-DO,
HLA-DP, HLA-DQ, and HLA-DR which are present in
antigen-presenting cells and bind extracellular antigens in
order to present them to T cells; and MHC class III region
contains genes that play important roles in immune re-
sponse including several components of complement (C2,
C4, and factor B), tumor necrosis factor (tumor necrosis
factor-alpha, lymphotoxin alpha, and lymphotoxin beta),
and heat shock protein. Both MHC class I and class II are
expressed on the cell surface to present antigens to the T
lymphocytes in order to initiate immune response.
Among the MHC class II genes, more than 1,500 dif-
ferent alleles have been identified, and studies have pro-
vided evidence that MHC class II are associated with
various autoimmune diseases [21-23]. MHC class II
genes are expressed on activated T cells and antigen-
presenting cells including dendritic cells, macrophages,
and B cells. Both the α- and β-chain genes are present in
each subregion of DR, DP, and DQ and form a specific
MHC class II molecule [20]. A number of HLA geno-
types have been strongly linked with VKH disease, and
these include HLA-DR and HLA-DQ (Tables 1 and 2).
HLA-DQ
Islam et al. conducted a study in Japanese VKH patients
and found that HLA-DQ4 and HLA-DQA1*0301 werepresent in 83% and 100% of VKH patients, respectively,
compared with 32% and 67%, respectively, in control
subjects, with HLA-DQA1*0301/-DR4 showing the
highest risk ratio (Table 1) [24]. The study also showed
that HLA-DQB1*0604 could not be detected in any
VKH patient, and therefore, it might offer some protec-
tion against VKH disease by modifying the pathogenesis
of VKH [24].
HLA-DR
A large number of studies have shown that VKH disease is
strongly associated with various HLA-DR alleles (Table 1)
[25]. HLA-DR4 of MHC class II was first found to be as-
sociated with VKH disease in Japanese in 1976 [26]. Since
then, studies have demonstrated that HLA-DR4 is strongly
associated with VKH patients of different ethnic groups
(Tables 1 and 2) including North Americans [27], Chinese
[25], Japanese [28,29], Hispanics [30-32], Italians [33],
ethnically heterogeneous Brazilian [34], Koreans [35], and
Saudi Arabians [36].
Over two decades ago, Goldberg et al. demonstrated
that HLA-DRB1*0405 was a major allele responsible for
susceptibility to develop VKH disease in Brazilian pa-
tients which is a highly admixed population [34]. In the
study [34], the diverse alleles initially suggested to be associ-
ated with VKH disease occurred independently, strengthen-
ing the significance of HLA-DRB1*0405 in the pathogenesis
of VKH. The frequency of HLA-DRB1*0405 was also sig-
nificantly higher in Japanese patients with prolonged type of
VKH disease [37]. Further studies have demonstrated that
patients with VKH disease who were HLA-DRB1*0405-
positive recognized a greater range of melanocyte epitopes
than HLA-matched control subjects [38], consolidating
the influence of HLA-DRB1*0405 in affecting the suscep-
tibility to VKH disease.
In addition to HLA-DRB1*0405 mentioned above,
HLA-DRB1*0407 and HLA-DRB1*0410 alleles were also
found to have increased frequency in Mestizo patients liv-
ing in southern California [32]. It was also found that the
frequency of HLA-DRB1*0410 was increased in Japanese
patients with VKH disease [24,28,39]. Increased frequen-
cies of HLA-DRB1*0405 and HLA-DRB1*0404 were iden-
tified in Mexican Mestizo VKH patients with odds ratios
of 2.95 and 2.79, respectively [40]. The serotype HLA-
DR1 has also been suspected as having a possible associ-
ation with VKH disease [30]. However, alleleic analyses
did not find a significant association between HLA-DRB1
alleles with VKH disease [36].
S57-LLEQRRAA (67-74) located in the third hypervar-
iable region of the HLA-DRB1 molecule is a shared epi-
tope of the two HLA-DRB1*0405 and HLA-DRB1*0410
alleles [41]. This shared epitope was found to be linked
with VKH disease in Indian patients [41]. Results from
alleleic and epitopic studies have demonstrated that
Table 1 Major HLA genotypes associated with VKH disease
HLA genotype association Major findings Race References
HLA-DQA1*0301 100% of 57 VKH patients vs. 67.2% of 122 control subjects Japanese Islam et al. [24]
HLA-DQB1*0604 0% of 57 VKH patients vs. 15.6% of 122 control subjects,
i.e., may be protective against VKH disease
Japanese Islam et al. [24]
HLA-DRB1*0404 25% of 76 VKH patients vs. 9.8% of 256 healthy individuals Mexican Mestizo Alaez et al. [40]
HLA-DRB1*0405 95% of 40 VKH patients vs. 58.2% of DR4-positive healthy controls Japanese Shindo et al. [28]
54.1% of 37 VKH patients have HLA-DRB1*0405 with a relative
risk of 11.76 over the general population
Highly admixed Brazilian Goldberg et al. [34]
82.3% of 18 VKH patients vs. 9.3% of 128 control subjects Korean Kim et al. [35]
36.6% of 30 VKH patients vs. 6.9% of 29 control subjects Saudi Arabian Iqniebi et al. [36]
13.2% of 76 VKH patients vs. 0.4% of 256 healthy individuals Mexican Mestizo Alaez et al. [40]
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VKH disease. However, complex associations between
different epitopes and VKH disease are expected due to
the high variability of HLA and the differences in genetic
profiles across different ethnic populations [42,43].
Although multiple studies have shown that the genetic
predisposition to VKH disease is contributed by multiple
overlapping factors encoded by the HLA system, the
strengths of association between HLA-DRB1*04 subtypes
and VKH disease vary among different races, indicating
that the pathogenesis of VKH may be multifactorial
with additional genetic susceptibility and environmen-
tal causes [32,34].Cytotoxic T-lymphocyte antigen 4 gene
Cytotoxic T-lymphocyte antigen 4 (CTLA-4) gene is lo-
cated on chromosome 2q33 and is expressed in activated
T cells and inhibits T cell activation by CD28 [44]. Over
100 single-nucleotide polymorphisms (SNPs) have been
identified in CTLA-4 gene regions, and some of these SNPs
were found to be related to immune-mediated diseases in-
cluding type 1 diabetes mellitus [45], multiple sclerosis [46],
systemic lupus erythematosus (SLE) [47], rheumatoid arth-
ritis [48,49], Hashimoto's thyroiditis, and Graves' disease
[45]. However, some of the studies showed conflictingTable 2 Major HLA serotypes associated with VKH disease
HLA serotype association Major findings
HLA-DQ4 83% of 57 VKH patients vs. 32% of 4
HLA-DQw7 59.4% of 32 VKH patients vs. 36.5% o
HLA-DR1 36% of 25 VKH patients vs. 9% of 21
HLA-DR4 75% of 32 VKH patients vs. 23.1% of
93% of 57 VKH patients vs. 43% of 4
56% of 25 VKH patients vs. 29% of 2
HLA-DR53 98.2% of 57 VKH patients vs. 67.5% oresults in the association of CTLA-4 gene polymorphisms
and autoimmune diseases [50-52].
A study of Chinese Han patients with VKH disease pro-
vided evidence that the G allele at SNP +49 of CTLA-4
was associated with VKH disease, and the CTLA-4 haplo-
type −1661A:−318C:+49G:CT60G was also found to con-
fer risk of VKH disease [53]. The CTLA-4 haplotype has
been shown to be associated with other types of uveitis,
and this can be due to differences in the pathogenesis
mechanisms among different uveitis entities [53].Complement system
The complement system is an essential component of
the primary immune system, and it plays a key role in
regulating various immunological and inflammatory re-
sponses. It has been demonstrated that experimental
autoimmune uveoretinitis (EAAU) can be caused by ac-
tivation of the complement system, and depletion of the
host's complement system can completely inhibit the
EAAU [54,55]. Yang et al. have shown that in Chinese
females, the 184G rs800292 polymorphism of comple-
ment factor H (CFH) gene is a genetic risk marker of an-
terior uveitis [56]. Another study also showed that the
carrier frequency of G allele of CFH-rs800292 is in-
creased in patients with non-infectious intermediate andRace References
61 control subjects Japanese Islam et al. [24]
f 52 control subjects Japanese Zhang et al. [25]
7 control subjects Hispanic Weisz et el [30]
52 control subjects Chinese Zhang et al. [25]
61 control subjects Japanese Islam et al. [24]
17 control subjects Hispanic Weisz et el [30]
f 461 control subjects Japanese Islam et al. [24]
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associated with VKH disease have not yet been discovered.
Interleukin genes
Interleukins (ILs) are produced by leukocytes and are
potent inflammatory mediators which are heavily in-
volved in numerous immunological diseases [58-60] in-
cluding diverse entities of uveitis [59,61-63]. Studies
have demonstrated that various interleukins may be as-
sociated with VKH disease (Table 3).
Interleukin-12B gene
Interleukin-12 (IL-12) is critical in the differentiation of
naïve T cells into Th1 cells [64] and was identified to be
involved in the pathogenesis of Behcet's disease [65,66].
Recently, C allele of rs3212227 of the IL-12B gene was
shown to be a significant risk factor of VKH disease [67].
Interleukin-17 gene
Upregulation of interleukin-17 (IL-17) was identified to
be associated with intraocular inflammation in patients
of VKH disease and Behçet's disease [68]. It was also
shown that rs763780 of IL-17F was associated with VKH
disease in Chinese Han population, with the TT geno-
type increasing the susceptibility of VKH disease and the
C allele of rs763780 being possibly protective against
VKH disease [69]. However, since only two SNPs of the
IL-17 gene were tested in the study [69], further studies
are needed to evaluate if the other polymorphisms of the
IL-17 gene are also associated with VKH disease.
Interleukin-23 receptor gene
Interleukin-23 (IL-23) was identified to be an important
cytokine in the development of autoimmune diseases
[70,71]. It enhances the production of IL-17 by CD4+ T
cells and contributes to the maintenance of various
autoimmune diseases [72]. Previous study has found that
the levels of IL-23 in the serum of VKH patients with ac-
tive uveitis were significantly higher than those without
active uveitis and normal controls [68]. However, no stat-






IL-12B rs3212227 C allele of rs3212227 of IL-12B is a risk fa
to enhance Th1 production which is in
IL-17F rs763780 TT genotype of IL-17F-rs763780 predisp
the C allele of rs763780 may have prote
IL-23R None discovered yet. IL-23 levels are increased in the serum
enhances production of IL-27 by CD4+
IL-27 None discovered yet. IL-27 is suggested to promote Th17 p
pathogenesis of VKH disease.polymorphisms (rs17375018, rs7517847, rs11209032, and
rs1343151) of interleukin-23 receptor (IL23R) gene in
VKH patients from a Chinese Han population [73]. In
view of the discrepancy between the SNP analysis and the
current understanding in the functions of IL-23 in uveitis,
more SNPs in the IL23R gene should be explored to inves-
tigate its association with VKH disease.
Interleukin-27 gene
Interleukin-27 (IL-27) is expressed in photoreceptors
and retinal ganglion cells [74]. It enhances the differenti-
ation of naïve T cells into Th1 cells but suppresses naïve
T cells from differentiating into Th17 cells, resulting in
mutual antagonism of Th1 and Th17 cells which are
both involved in the pathogenesis of uveitis [75,76].
Nonetheless, a previous study by Yang et al. showed no
association between the rs4788084 SNP of IL-27 and
intermediate uveitis and posterior uveitis [57].
Killer cell immunoglobulin-like receptor gene cluster
The killer cell immunoglobulin-like receptor (KIR) genes
on chromosome 19 encode inhibitory (3DL1, 3DL2, 3DL3,
2DL1, 2DL2, 2DL3, and 2DL5) and activating (3DS1,
2DS1, 2DS2, 2DS3, 2DS4, 2DS5) receptors which are
expressed on the majority of natural killer (NK) cells and a
small proportion of T cells [77]. The inhibitory KIRs
recognize distinct HLA class I molecules and stop the ef-
fector function of NK cells, thus offering protections to
healthy cells. Expression of HLA class I molecules protect
healthy cells from surveillance of NK cells [78].
KIR2DS3 was found to be more frequent in VKH pa-
tients than in the control group in a study performed in
Saudi Arabia [79]. Another study by Levinson et al.
showed that the frequency of KIR gene cluster 3DS1-
2DL5-2DS1-2DS5 was higher and increased the suscepti-
bility to VKH disease in Japanese patients [80]. Therefore,
it was suggested that the KIR genes that encode activating
KIR receptors may increase the risk of VKH disease. On
the other hand, KIR-HLA interactions might be involved
in the protection against VKH disease and might possibly
reduce the severity of VKH disease as KIR2DL2/2DL3+associated with VKH disease
Race References
ctor of VKH disease. IL-12B is suggested
volved in the pathogenesis of VKH disease.
Chinese Han Li et al. [67]
oses susceptibility to VKH disease, whereas
ctive effects against VKH disease.
Chinese Han Shu et al. [69]
of VKH patients with active uveitis. IL-23
T cells.
Chinese Han Jiang et al. [73]
roduction which is involved in the Chinese Han Yang et al. [57]
Ng et al. Journal of Ophthalmic Inflammation and Infection 2014, 4:20 Page 5 of 12
http://www.joii-journal.com/content/4/1/20HLA-C1 was identified to have a higher frequency in
the control group [79]. However, the direct role of NK
cells in the pathogenesis of VKH disease has not yet been
established.Programmed cell death 1 gene
Programmed cell death 1 (PDCD1) on chromosome 2q37
encodes programmed cell death 1 (PD-1) which induces
apoptotic cell death of murine lymphoid cell lines in vitro
[81]. It has been suggested to suppress the development of
inflammatory helper T cells modulating the innate im-
mune system [82]. PDCD1 has been shown to be involved
in a wide range of autoimmune diseases including Graves'
disease [83], type I diabetes [84], ankylosing spondylitis
[85], rheumatoid arthritis [86,87], SLE [88-91], and mul-
tiple sclerosis [92]. However, several studies have shown
contradictory results [93-97]. In Chinese Han population,
the frequency of C allele in PD-1.5 was found to be sig-
nificantly lower in VKH patients with poliosis or with
dysacusis compared with control subjects, suggesting
that PD-1.5 may influence the extraocular manifestations
among VKH patients [98]. In the same study, no associ-
ation was found among VKH disease and the SNPs PD-
1.3 and PD-1.6 [98].Protein tyrosine phosphatase non-receptor 22 gene
Protein tyrosine phosphatase non-receptor 22 (PTPN22)
influences the development and activation of lymphocytes,
innate cell-mediated immune host defense, formation of
tolerance, and regulation of the immune system [99].
PTPN22 is located on chromosome 1p13.3 to 1p13.1 and
encodes the lymphoid-specific phosphatase known as Lyp
which plays an essential suppressive role in T cell activation
[100]. Several studies have demonstrated that a SNP in
PTPN22, R620W (rs2476601), predisposes individuals to
various autoimmune diseases including insulin-dependent
diabetes mellitus [101], rheumatoid arthritis [102,103],
Graves' disease [104], and SLE [105]. In a study of 67 Japanese
patients with VKH disease [106], six SNPs in PTPN22
(rs3811021, rs1217413, rs1237682, rs3761935, rs3789608,
and rs2243471) were shown to have no significant associ-
ation with VKH disease. However, in a study of 1,005
VKH patients and 2,010 healthy controls of Han Chinese
population [107], significantly increased frequencies of
rs2488457 CC genotype and C allele were found in VKH
patients. Moreover, there was decreased frequency of
rs2488457 GG genotype in patients with VKH disease. No
significant association between T cell activation and
rs2488457 genotype was observed [107]. It was proposed
that a functional variant rs2488457 in PTPN22 increases
susceptibility to VKH disease via modulating the expres-
sion of PTPN22, production of interleukin 10 (IL-10) and
proliferation of peripheral blood mononuclear cells [107].Osteopontin gene
The osteopontin (OPN) gene encodes osteopontin which
is a pro-inflammatory cytokine involved in chronic inflam-
matory diseases [108,109]. It was shown that serum levels
of OPN were significantly higher in patients with active
VKH disease than in patients with inactive VKH disease
and in the control group [110]. In the same study [110],
recombinant OPN was shown to induce a significant in-
crease in the proliferation of CD4+ T cells and secretion of
interferon gamma and IL-17 in patients with active VKH
disease. The frequency of the TT genotype of OPN rs4754
was also shown to be positively correlated with VKH dis-
ease in Chinese Han population [110].Tumor necrosis factor, alpha-induced protein 3 gene
Tumor necrosis factor, alpha-induced protein 3 (TNFAIP3)
gene encodes the A20 protein which is a cytoplasmic zinc
finger protein. The A20 protein prevents the over-reaction
of innate immune responses by suppressing TNF-induced
signaling and negatively regulating nuclear factor kappa B
(NF-κB) responses mediated by innate immune receptors
including TNF receptor [111,112]. TNFAIP3 polymor-
phisms were found to predispose to autoimmune diseases
including rheumatoid arthritis [113,114], psoriasis [115],
and SLE [116,117]. A study by Li et al. in VKH patients has
found that the rs9494885 TC genotype and C allele may
confer a risk to VKH disease, while the rs9494885 TTgeno-
type and T allele may protect against VKH disease [118].Macrophage migration inhibitory factor gene
The macrophage migration inhibitory factor (MIF) gene
on chromosome 22q11.2 plays an important role in the
level of MIF expression in macrophages and T cells, as
well as release of other inflammatory cytokines [119].
SNPs in the MIF gene have been shown to be involved
in a number of immunological diseases including psoria-
sis [120], SLE [121], ulcerative colitis [122], juvenile idio-
pathic arthritis [123,124], and multiple sclerosis [125].
The levels of MIF were also found to be significantly
higher in uveitis patients with VKH disease, sarcoidosis,
and Behçet's disease [126,127]. In a study by Zhang et al.
[128], the frequencies of GG genotype and G allele of
rs755622 in the MIF gene were found to be significantly
lower in VKH patients than in controls. The frequency of
T allele of rs2096525 was also significantly lower in pa-
tients with headache or vitiligo than in the control group
[128]. Therefore, the GG genotype and G allele may be
protective factors for VKH disease, while the T allele of
rs2096525 may be a risk factor for non-ocular manifest-
ation of VKH disease [128]. The study also demonstrated
that the combined rs755622/rs2096525 CT haplotype
confers an increased risk to VKH disease, whereas the GT
haplotype reduces the susceptibility to VKH disease [128].
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Tyrosinase gene family is specifically expressed in mela-
nocytes, and it encodes the enzymes that forms melanin
[129]. Mutations of tyrosinase gene family are related to
depigmentation and developmental defects of the eye in-
cluding oculocutaneous albinism type 1 (OCA1) and
microphthalmia [130-133]. Lymphocytes of patients with
VKH disease were shown to be reactive to peptides derived
from tyrosinase family proteins, thus it is possible that
tyrosinase and tyrosinase-related proteins could be the
auto-antigens in VKH disease [1]. However, a study evalu-
ating polymorphisms of microsatellites loci in tyrosinase
gene family among Japanese VKH patients has failed to
find a significant association with VKH disease [134].
Interferon gamma gene
Previous studies have demonstrated elevated levels of
interferon gamma in the aqueous humor and serum of
patients with VKH disease [135,136]. However, a study
evaluating gene polymorphism of interferon gamma gene
and VKH disease found no significant difference in the
frequencies of alleles and genotypes of interferon gamma
gene between VKH patients and healthy controls [137].
NLR family, pyrin domain containing 1 gene
NLR family, pyrin domain containing 1 (NLRP1) gene on
chromosome 17p13 is involved in the primary immune
system and was shown to be associated with generalized
vitiligo and other autoimmune diseases [138-141]. Since
skin hypopigmentation in VKH disease resembles general-
ized vitiligo, NLRP1 might be involved in the pathogenesis
of VKH. However, a study by Horie et al. has shown that
NLRP1 gene polymorphisms related to vitiligo were not
associated with the risks or clinical manifestations of VKH
disease, and this suggests that the genetic and immune
factors associated with VKH disease are likely to be dis-
tinct from generalized vitiligo [142].
Toll-like receptor 9 gene
Toll-like receptor 9 (TLR9) recognizes unmethylated 2′-
deoxyribo(cytidine-phosphate-guanosine) (CpG) dinucleotide
motifs in viruses and is of importance in the immuno-
logical defense against viral infections [143]. TLR9 has
been postulated to be one of the candidate genes in the
pathogenesis of VKH, but a study by Ito et al. has failed to
find a significant association between TLR9 polymorphisms
and VKH disease [144].
Transforming growth factor β receptor gene
Transforming growth factor β ((TGF-β) influences the
differentiation of Th17 [145-147], and two SNPs of type
III TGF-β receptor (rs1805110 and rs2489188) have
been investigated to determine their association with
VKH disease in Chinese Han population [148]. Thesetwo SNPs were shown not to be associated with VKH
disease, whereas rs2489188 CC genotype of the type III
TGF-β receptor was shown to be protective against
Behcet's disease [148].
Janus kinase 1 gene
Janus kinase 1 (JAK1) is an essential component of the
human immune system which regulates cell differenti-
ation of Th1 and Th17 [149]. A recent study suggested
that three SNPs of the JAK1 gene including GG geno-
type of rs310230, GG genotype of rs310236, and TT
genotype of rs310241 were found to occur in lower fre-
quencies in VKH patients than control subjects [150].
However, no significant link between the three SNPs and
clinical manifestations of VKH disease was identified,
and currently, there is no published data on the func-
tional role of these SNPs of JAK1 [150].
Fibroblast growth factor receptor 1 oncogene partner
and chemokine (C-C motif) receptor 6 genes
Both fibroblast growth factor receptor 1 oncogene partner
(FGFR1OP) and chemokine receptor 6 (CCR6) are encoded
by a linkage disequilibrium block located on chromosome
6q27 [151], and both have been identified to be associated
with susceptibility of vitiligo. Moreover, the two genes have
been implicated in the pathogenesis of autoimmune dis-
eases as CCR6 was found to be associated with Crohn's
disease [152], ulcerative colitis [153], and rheumatoid
arthritis [154,155], while FGFR1OP was found to be re-
lated to Graves' disease [156] and myeloproliferative disor-
ders [157,158] and is involved in microtubule anchoring at
the centrosome [159]. Two independent case-control co-
horts of Chinese Han population have shown that the A
allele of rs2301436 of FGFR1OP is associated with suscep-
tibility to VKH, whereas no association was found for the
four tested CCR6 SNPs including rs3093024, rs6902119,
rs3093023, and rs968334 [160].
Limitations of genetic studies in VKH disease
Although genetic studies have contributed greatly in identi-
fying mechanisms involved in the pathogenesis of VKH
disease, they are not without any limitation. Firstly, there
may be linkage disequilibrium in the genetic analysis, i.e.,
the occurrence of certain combinations of alleles or genetic
markers in a population more frequently or less frequently
than these would be expected from a totally random for-
mation of haplotypes from alleles based on their original
frequencies. Linkage equilibrium occurs when there is non-
random correlation among neighboring alleles that descend
from single ancestral chromosomes [161]. The genetic asso-
ciation found in the different studies may be in linkage dis-
equilibrium with the causative locus, thereby leading to
confounding of the results. Secondly, the effects of geno-
types on phenotypes found in many of the research are not
Table 4 Summary of genes that have been shown to be related to increased risk of VKH disease
Gene Subtype/polymorphism References
Human leukocyte antigen (HLA) HLA-DQ4 Islam et al. [24]
HLA-DQw7 Zhang et al. [25]
DR1 Weisz et el. [30]
DR4 Islam et al. [24],
Zhang et al. [25],
Weisz et el. [30]
DR53 Islam et al. [24]
Cytotoxic T-lymphocyte antigen 4 (CTLA-4) G allele at SNP +49, CTLA-4 haplotype −1661A:−318C:+49G:CT60G Du et al. [53]
Interleukin (IL) genes IL-12B rs3212227 C allele Li et al. [67]
IL-17F rs763780 TT genotype Shu et al. [69]
Killer cell immunoglobulin-like receptors
(KIR) gene cluster
KIR2DS3, KIR gene cluster 3DS1-2DL5-2DS1-2DS5,
KIR2DL2/2DL3+HLA-C1
Sheereen et al. [79]
Programmed cell death 1 (PDCD1) PD-1.5 C allele Meng et al. [98]
Protein tyrosine phosphatase non-receptor 22 (PTPN22) rs2488457 CC genotype and C allele Zhang et al. [107]
rs2488457 GG genotype
Osteopontin (OPN) rs4754 TT genotype Chu et al. [110]
Tumor necrosis factor, alpha-induced protein 3 (TNFAIP3) rs9494885 TC genotype and C allele Li et al. [118]
Macrophage migration inhibitory factor (MIF) rs755622 GG genotype and G allele, rs2096525
T allele, rs755622/rs2096525 CT haplotype
Zhang et al. [128]
Fibroblast growth factor receptor
1 oncogene partner (FGFR1OP)
rs2301436 Yi et al. [160]
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http://www.joii-journal.com/content/4/1/20clearly known, and therefore, exactly how the SNPs affect
the inflammatory proteins and their receptor functions re-
mains uncertain. Therefore, whether the manipulations of
these inflammatory proteins in patients with certain geno-
types would be able to alter the course of VKH disease re-
main to be seen.Table 5 Summary of genes which have been shown to be unr
Gene Subtype/polymorphism
Complement factor H (CFH) 184G rs800292 showed incre
and posterior uveitis but no
Tyrosinase gene family No significant association in
tyrosinase gene family was f
Interferon gamma No significant association in
was found in Japanese VKH
NLR family, pyrin domain containing 1 (NLRP1) NLRP1 gene polymorphisms
the risks or clinical manifesta
Toll-like receptor 9 (TLR9) gene No significant association be
was found in VKH patients.
Transforming growth factor β receptor (TGF-β) Two SNPs of type III TGF-β r
no association with VKH dise
Janus kinase 1 (JAK1) gene rs310230 GG genotype, rs310
found in lower frequencies in
link between the three SNPs
Chemokine (C-C motif) receptor 6 (CCR6) No significant association in
rs3093023, and rs968334 in CConclusion
In recent years, advancement in research has shed some
light on the genetic basis and mechanisms of uveitis in-
cluding VKH disease. Multiple studies have demon-
strated that genetic polymorphisms may influence the
expression of genes or the functions of gene productselated or with uncertain association with VKH disease
References
ased risk with non-infectious intermediate
t in VKH.
Yang et al. [56]
polymorphisms of microsatellites loci in
ound in Japanese VKH patients.
Horie et al. [134]
polymorphism of interferon gamma gene
disease.
Horie et al. [137]
related to vitiligo were not associated with
tions of VKH disease.
Horie et al. [142]
tween TLR9 polymorphisms and VKH disease Ito et al. [144]
eceptor, rs1805110 and rs2489188, showed
ase.
Chen et al. [148]
236 GG genotype, and rs310241 TT genotype were
VKH patients than controls. However, no significant
and clinical manifestations of VKH disease was identified.
Hu et al. [150]
CCR6 SNPs including rs3093024, rs6902119,
hinese VKH patients.
Yi et al. [160]
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http://www.joii-journal.com/content/4/1/20and affect the susceptibility of VKH disease (Tables 4 and
5). Some of the major genetic factors involved in immune
response associated with uveitis include HLA genes and
non-HLA genes such as CTLA-4, ILs, and KIR. The auto-
immune response against melanocytes in VKH disease
involves a large variety of genes including variants of
HLA genes, multiple ILs, and other cytokines and genes
involved in the immune pathway. Since each individual
gene may have an independent but small effect on the sus-
ceptibility and clinical manifestations of VKH disease, this
increases the challenge of finding the genetic culprit in
pathogenesis of VKH disease.
For future directions of genetics study on VKH disease,
in-depth genome-wide scans with fine mapping and exo-
mic sequencing with replications in different ethnic groups
will be important for revealing novel genetic regions asso-
ciated with VKH disease. Detailed studies on correlations
of various genotypes and phenotypes of VKH disease
should also be carried out. These findings will greatly en-
hance our understanding in the role of genetic factors in
the pathogenesis of VKH disease and will be useful in pre-
dicting treatment response and developing more targeted
treatment and possible gene therapy.
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